Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Asahi Intecc CoFRA:6XT -0.95%97 EV-to-EBITDA is 16.78 as of Aug. 12, 2026, which is 55% below its 10-year median of 37.14. GuruFocus rates FRA:6XT with a GF Score™ of 97/100 and a GF Value™ of €18.21 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 515 Medical Devices & Instruments companies, Asahi Intecc Co ranks worse than 57.28% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Asahi Intecc Co's enterprise value is €5,345.5 Mil.
Asahi Intecc Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €318.6 Mil. Therefore, Asahi Intecc Co's EV-to-EBITDA for today is 16.78.
The historical rank and industry rank for Asahi Intecc Co's EV-to-EBITDA or its related term are showing as below:
FRA:6XT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.49 Med: 37.14 Max: 96.21
Current: 17.36
During the past 13 years, the highest EV-to-EBITDA of Asahi Intecc Co was 96.21. The lowest was 16.49. And the median was 37.14.
FRA:6XT's EV-to-EBITDA is ranked worse than 57.28% of 515
companies
in the Medical Devices & Instruments industry
Industry Median: 14.92
vs FRA:6XT: 17.36
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Asahi Intecc Co (FRA:6XT) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Asahi Intecc Co's PE Ratio (TTM) for today is calculated as:
Asahi Intecc Co's share price for today is €20.80.
Asahi Intecc Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.645.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Asahi Intecc Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6XT vs ISRG, BDX, MDLN: EV-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Asahi Intecc Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asahi Intecc Co EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Asahi Intecc Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Asahi Intecc Co's EV-to-EBITDA falls into.
Asahi Intecc Co's current Enterprise Value is €5,345.5 Mil.
Asahi Intecc Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €318.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asahi Intecc Co (FRA:6XT) has a EV-to-EBITDA of 16.78 as of Aug. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Asahi Intecc Co. This is 55% below median its historical median of 37.14. Over the past decade, Asahi Intecc Co's EV-to-EBITDA has ranged from 16.49 to 96.21. According to the industry distribution chart, Asahi Intecc Co ranks #295 out of 515 companies in the Medical Devices & Instruments industry, placing it in the top 57.3%.
Is Asahi Intecc Co's EV-to-EBITDA too high?
Asahi Intecc Co's current EV-to-EBITDA of 16.78 is 55% below median its 10-year median of 37.14. Over the past 10 years, this metric has ranged from a low of 16.49 to a high of 96.21. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.92. Asahi Intecc Co's value of 16.78 is 12.5% above this industry median. Based on the distribution chart, Asahi Intecc Co ranks #295 out of 515 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Asahi Intecc Co has a GF Score™ of 97/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asahi Intecc Co's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Asahi Intecc Co ranks #295 out of 515 companies for EV-to-EBITDA. This places Asahi Intecc Co in the lower half of its industry. The industry median EV-to-EBITDA is 14.92. Asahi Intecc Co's value of 16.78 is 12.5% above this benchmark. Historically, Asahi Intecc Co's own EV-to-EBITDA has ranged from 16.49 to 96.21 over the past decade. While the company's 10-year median is 37.14 vs. the industry median of 14.92, Asahi Intecc Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.92, based on 515 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asahi Intecc Co's current EV-to-EBITDA of 16.78 is 12.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Asahi Intecc Co. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asahi Intecc Co's current EV-to-EBITDA is 16.78, which is 55% below median its own 10-year median of 37.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asahi Intecc Co stock overvalued right now?
Based on GuruFocus' analysis, Asahi Intecc Co (FRA:6XT) is currently considered Modestly Overvalued. The stock's GF Value™ is €18.21, compared to a current price of €20.80 — trading 14.2% above its estimated fair value. The current EV-to-EBITDA is 16.78, which is 55% below median its 10-year median of 37.14 and 12.5% above the Medical Devices & Instruments industry median of 14.92. Asahi Intecc Co's overall GF Score™ is 97/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Asahi Intecc Co (FRA:6XT), the current EV-to-EBITDA is 16.78 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asahi Intecc Co (FRA:6XT) Overvalued in 2026?
Based on GuruFocus' analysis, Asahi Intecc Co stock appears to be overvalued.
The current stock price of €20.80 is trading 14.2% above its estimated GF Value™ of €18.21.
GuruFocus considers Asahi Intecc Co to be Modestly Overvalued.
Key valuation signals for FRA:6XT:
EV-to-EBITDA: 16.78 (55% below median its 10-year median of 37.14)
GF Value™: €18.21 vs. price of €20.80 (14.2% above fair value)
Industry Position: 12.5% above the Medical Devices & Instruments median (#295 of 515)
No single metric tells the full story. See the FRA:6XT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asahi Intecc Co Ltd is engaged in the development, manufacturing, and sales of medical and industrial equipment components. The company operates through two reportable segments: Medical Business and Device Business. The Medical Business develops, manufactures, and sells proprietary and OEM products in the medical equipment field, while the Device Business focuses on components for medical and industrial equipment applications. It generates the majority of its revenue from the Medical Business segment.
97GF Score
Get the complete analysis for FRA:6XT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6XT has been successfully added to your 
